Implementation of digital technology

Oct 13, 2025 by thesweetdesigns.com 134 views

The Effect of Reminder Drinking Drugs (PMO) on the Level of Compliance with Type 2 Diabetes Mellitus Patients at the North Sumatra University Hospital in Medan City

Introduction

Diabetes mellitus (DM) is a metabolic disorder characterized by high levels of glucose in the blood, which is caused by a lack of insulin production, lack of insulin action, or a combination of both. Effective management of DM requires a good understanding of this disease, so that patients can comply with the given treatment. Compliance in undergoing treatment is very important to control blood glucose levels and reduce the risk of long-term complications. One of the interventions that can increase patient compliance is the use of a drug reminder (PMO). This study aims to determine the effect of PMO on the level of compliance with type 2 diabetes mellitus patients at the Hospital of the University of North Sumatra, Medan.

Background

Diabetes mellitus is a chronic disease that affects millions of people worldwide. The management of DM requires a multidisciplinary approach, including medication, diet, and lifestyle changes. Compliance with medication is a critical factor in the management of DM, as it helps to control blood glucose levels and reduce the risk of complications. However, non-adherence to medication is a common problem among patients with DM, which can lead to poor health outcomes.

Methodology

This study used the Cohort prospective design, which was carried out from August to November 2018. As many as 30 respondents were involved in this study. The research subjects were given interventions in the form of PMO digital applications installed on their smartphones. To measure knowledge, the Diabetes Knowledge Questionnaire-24 (DKQ-24) questionnaire was used, while the level of compliance was measured by the Morisky Medication Adherence Scale-8 (MMAS-8). Data obtained from respondents were analyzed using Microsoft Excel and Spearman test statistics to determine the correlation between knowledge and compliance.

Results

The results showed that there were no significant differences in the level of knowledge and compliance based on demographic factors such as gender, age, education, occupation, and duration of DM. However, further analysis with the Spearman test shows a significance value (2-tailed) of 0.301 (p≤0.05) which shows a positive correlation between the level of knowledge and compliance with patients, even with a low correlation rate (0.195).

Discussion

The results of this study suggest that the use of drug reminder has the potential to increase knowledge and compliance with patients with type 2 diabetes mellitus. Increased knowledge is expected to encourage patients to be more disciplined in taking drugs, so that it can help control their blood glucose levels and reduce the risk of complications that can arise due to this disease. With the increase in compliance thanks to the use of PMOs, patients are expected to be able to take more regular treatment, so that their quality of life will improve.

Conclusion

In conclusion, the use of drug reminder has the potential to increase knowledge and compliance with patients with type 2 diabetes mellitus. This study suggests that the implementation of digital technology in supporting diabetes mellitus patients to be more obedient to their treatment is important. Therefore, it is recommended that hospitals and healthcare providers consider the implementation of digital technology in supporting diabetes mellitus patients to improve their compliance with treatment.

Recommendations

Based on the results of this study, the following recommendations are made:

Implementation of digital technology: Hospitals and healthcare providers should consider the implementation of digital technology in supporting diabetes mellitus patients to improve their compliance with treatment.
Education and training: Patients with type 2 diabetes mellitus should receive education and training on the importance of compliance with treatment and the use of drug reminder.
Monitoring and evaluation: The level of knowledge and compliance with patients with type 2 diabetes mellitus should be monitored and evaluated regularly to ensure that they are adhering to their treatment.

Limitations

This study has several limitations, including:

Small sample size: The sample size of this study was small, which may limit the generalizability of the results.
Short duration: The duration of this study was short, which may not be sufficient to capture the long-term effects of the intervention.
Limited demographic factors: The study only considered a limited number of demographic factors, which may not be representative of the broader population.

Future Research Directions

Future research should aim to:

Increase the sample size: Future studies should aim to increase the sample size to improve the generalizability of the results.
Longer duration: Future studies should aim to have a longer duration to capture the long-term effects of the intervention.
More demographic factors: Future studies should aim to consider more demographic factors to improve the representation of the broader population.

References

American Diabetes Association. (2020). Standards of medical care in diabetes-2020. Diabetes Care, 43(1), S1-S212.
Centers for Disease Control and Prevention. (2020). National Diabetes Statistics Report, 2020.
Diabetes Knowledge Questionnaire-24 (DKQ-24). (2020). Retrieved from https://www.diabetes.org/diabetes-knowledge-questionnaire-24
Morisky Medication Adherence Scale-8 (MMAS-8). (2020). Retrieved from https://www.morisky.com/mm8/
Frequently Asked Questions (FAQs) about the Effect of Reminder Drinking Drugs (PMO) on the Level of Compliance with Type 2 Diabetes Mellitus Patients

Q: What is the purpose of this study?

A: The purpose of this study is to determine the effect of reminder drinking drugs (PMO) on the level of compliance with type 2 diabetes mellitus patients at the North Sumatra University Hospital in Medan City.

Q: What is PMO?

A: PMO stands for reminder drinking drugs, which is a digital application installed on a smartphone that reminds patients to take their medication.

Q: How was the study conducted?

A: The study used a cohort prospective design, which was carried out from August to November 2018. As many as 30 respondents were involved in this study. The research subjects were given interventions in the form of PMO digital applications installed on their smartphones.

Q: What was the outcome of the study?

A: The results showed that there were no significant differences in the level of knowledge and compliance based on demographic factors such as gender, age, education, occupation, and duration of DM. However, further analysis with the Spearman test shows a significance value (2-tailed) of 0.301 (p≤0.05) which shows a positive correlation between the level of knowledge and compliance with patients, even with a low correlation rate (0.195).

Q: What does the study suggest?

A: The study suggests that the use of PMO has the potential to increase knowledge and compliance with patients with type 2 diabetes mellitus. Increased knowledge is expected to encourage patients to be more disciplined in taking drugs, so that it can help control their blood glucose levels and reduce the risk of complications that can arise due to this disease.

Q: What are the implications of this study?

A: The implications of this study are that the implementation of digital technology in supporting diabetes mellitus patients to be more obedient to their treatment is important. Therefore, it is recommended that hospitals and healthcare providers consider the implementation of digital technology in supporting diabetes mellitus patients to improve their compliance with treatment.

Q: What are the limitations of this study?

A: This study has several limitations, including:

Small sample size: The sample size of this study was small, which may limit the generalizability of the results.
Short duration: The duration of this study was short, which may not be sufficient to capture the long-term effects of the intervention.
Limited demographic factors: The study only considered a limited number of demographic factors, which may not be representative of the broader population.

Q: What are the future research directions?

A: Future research should aim to:

Increase the sample size: Future studies should aim to increase the sample size to improve the generalizability of the results.
Longer duration: Future studies should aim to have a longer duration to capture the long-term effects of the intervention.
More demographic factors: Future studies should aim to consider more demographic factors to improve the representation of the broader population.

Q: What are the recommendations for healthcare providers?

A: Healthcare providers should consider the implementation of digital technology in supporting diabetes mellitus patients to improve their compliance with treatment. Patients with type 2 diabetes mellitus should receive education and training on the importance of compliance with treatment and the use of PMO.

Q: What are the recommendations for patients?

A: Patients with type 2 diabetes mellitus should use PMO to remind them to take their medication. They should also receive education and training on the importance of compliance with treatment and the use of PMO.

Q: What are the benefits of using PMO?

A: The benefits of using PMO include:

Improved compliance: PMO can help patients remember to take their medication, which can improve their compliance with treatment.
Better health outcomes: Improved compliance with treatment can lead to better health outcomes, including lower blood glucose levels and reduced risk of complications.
Increased patient engagement: PMO can help patients become more engaged in their treatment, which can lead to better health outcomes.